Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system and other disorders. Its lead programs include SLS-002, an intranasal racemic ketamine for acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, a gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein-targeted autophagy for Alzheimer disease. Founded in 2016 and headquartered in New York, New York, the company filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York on November 16, 2024.